Navigation Links
Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
Date:4/15/2008

ng statements. Such forward-looking statements include statements about the ability of Iomai's adjuvant patches to provide protective immune responses with one or two doses of H5N1 influenza vaccine; the significance of the results described in this press release to government health officials in addressing an outbreak of pandemic influenza; that the clinical trial data from the new clinical trial will be sufficient to proceed next with a pivotal Phase 3 clinical trial; that the characteristics of Iomai's adjuvant patch described in this press release would make the product ideal for stockpile and rapid distribution; the anticipated reimbursement for the costs associated with further testing of the adjuvant the patch and the potential future funding authorized by HHS. Applicable risks and uncertainties include, among others, that future clinical trials may not replicate results seen in the trial described in this press release; that the U.S. Food and Drug Administration or other regulatory authorities may not concur with Iomai's analysis of the trial results described in this press release; that Iomai may not be able to enroll sufficient numbers of subjects in future clinical trials; that Iomai may be unable to obtain the regulatory approvals or financing necessary to conduct additional clinical trials, or to develop the product to a point where the adjuvant patch can be sold to the government for stockpiling for its pandemic influenza program; that competitors may develop products that are safer, more effective, or more convenient to use; future clinical results may not support regulatory approval to commercialize Iomai's adjuvant patch for pandemic influenza applications, which will depend on the outcome of additional clinical trials and analysis by regulatory authorities of data Iomai submits; that Iomai may not meet its contractual milestones in order to fully perform under the contract and thereby receive complete reimbursement from HHS; that Congress will not
'/>"/>
SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
5. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. CryoCor Receives FDA Approval for Right Atrial Flutter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... BEIJING , May 14 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... marketing and,sale of medical products in China , today reported ... . , (Logo: http://www.newscom.com/cgi-bin/prnh/20100422/CNTH001LOGO ), ... for the first quarter ended March 31, 2010 increased 5% to, ...
... BEIJING , May 14 /PRNewswire-Asia-FirstCall/ -- ... growing developer,manufacturer and seller of medicine and drugs in the ... for the first quarter,ended March 31, 2010 . , , ... -- Diluted EPS of $0.09, up 27% from first ...
Cached Medicine Technology:Dehaier Medical Systems Announces First Quarter Net Income Up 54% 2Dehaier Medical Systems Announces First Quarter Net Income Up 54% 3Dehaier Medical Systems Announces First Quarter Net Income Up 54% 4Dehaier Medical Systems Announces First Quarter Net Income Up 54% 5Dehaier Medical Systems Announces First Quarter Net Income Up 54% 6Dehaier Medical Systems Announces First Quarter Net Income Up 54% 7Dehaier Medical Systems Announces First Quarter Net Income Up 54% 8Dehaier Medical Systems Announces First Quarter Net Income Up 54% 9Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 2Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 3Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 4Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 5Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 6Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 7Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 8Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 9Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 10
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... Pharmaceuticals,Inc. (Nasdaq: CADX ), a biopharmaceutical company ... principally,for use in the hospital setting, today announced ... before the market opens on Tuesday, May 6,2008., ... and live webcast to,discuss the financial results and ...
... to Both Reduce Exacerbations ... and Improve Lung Function, ... and Drug Administration today approved Advair Diskus(R) 250/50,(fluticasone propionate 250 ... exacerbations in patients with chronic obstructive,pulmonary disease (COPD) who have ...
... Phase of NHLBI-Sponsored Study on Children,s Physical Activity in Child Care ... at Pediatric Academic Societies ... Annual Meeting, CINCINNATI, ... 3-6) are in child care centers, and growing concern over,childhood obesity has ...
... prolapse a tear or weakness in a womans pelvic ... the body runs in families, a new Saint Louis ... has had a hernia or prolapse two conditions that ... more likely to develop prolapse themselves, says Mary McLennan, M.D., ...
... April 30 NightHawk,Radiology Holdings, Inc. (Nasdaq: ... radiology groups and hospitals throughout the United States,today ... appointed as an,independent member of the company,s Board ... change, the company has regained compliance with the ...
... FOREST, Ill., April 30 Hospira, Inc.,(NYSE: HSP ... announced that Thomas E. Werner, senior vice president,Finance, and ... Bank of America 2008 Health Care Conference on Wednesday, ... Vegas., The presentation is scheduled to begin at ...
Cached Medicine News:Health News:Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 3Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 4Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 2Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 3Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 4Health News:Family history places women at risk of pelvic organ prolapse, SLU research finds 2Health News:NightHawk Radiology Holdings, Inc. Announces Appointment of David Engert to the Board of Directors 2Health News:NightHawk Radiology Holdings, Inc. Announces Appointment of David Engert to the Board of Directors 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: